Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Hip To Be Square: Oxetanes as Design Elements To Alter Metabolic Pathways.

Toselli F, Fredenwall M, Svensson P, Li XQ, Johansson A, Weidolf L, Hayes MA.

J Med Chem. 2019 Aug 22;62(16):7383-7399. doi: 10.1021/acs.jmedchem.9b00030. Epub 2019 Aug 2.

PMID:
31310524
2.

Oxetane Substrates of Human Microsomal Epoxide Hydrolase.

Toselli F, Fredenwall M, Svensson P, Li XQ, Johansson A, Weidolf L, Hayes MA.

Drug Metab Dispos. 2017 Aug;45(8):966-973. doi: 10.1124/dmd.117.076489. Epub 2017 Jun 9.

PMID:
28600384
3.

Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.

Nordqvist A, O'Mahony G, Fridén-Saxin M, Fredenwall M, Hogner A, Granberg KL, Aagaard A, Bäckström S, Gunnarsson A, Kaminski T, Xue Y, Dellsén A, Hansson E, Hansson P, Ivarsson I, Karlsson U, Bamberg K, Hermansson M, Georgsson J, Lindmark B, Edman K.

ChemMedChem. 2017 Jan 5;12(1):50-65. doi: 10.1002/cmdc.201600529. Epub 2016 Dec 15.

PMID:
27897427
4.

Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties.

Johansson A, Löfberg C, Antonsson M, von Unge S, Hayes MA, Judkins R, Ploj K, Benthem L, Lindén D, Brodin P, Wennerberg M, Fredenwall M, Li L, Persson J, Bergman R, Pettersen A, Gennemark P, Hogner A.

J Med Chem. 2016 Mar 24;59(6):2497-511. doi: 10.1021/acs.jmedchem.5b01654. Epub 2016 Feb 5.

PMID:
26741166

Supplemental Content

Loading ...
Support Center